InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,011.12
(
-0.22%
)
US TECH 100
16,903.20
(
-0.77%
)
Dow Jones
37,775.38
(
0.06%
)
Brent Oil
88.88
(
2.85%
)
Bitcoin
61,172.29
(
-3.71%
)
Post# of 396422
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Let's Roll

Send PM Follow Ignore
Followers 883
Posts 304355
Boards Moderated 5
Alias Born 06/09/2006

Let's Roll

Re: None

Tuesday, 07/22/2014 11:09:25 AM

Tuesday, July 22, 2014 11:09:25 AM

Post# of 396422
GNSZ Dr. Craig Dionne, GenSpera CEO, recently said of its lead drug candidate G-202, based on the new data presented, "These positive results enable management to remain optimistic about our ambitious G-202 clinical development program which is expanding into glioblastoma, prostate cancer and renal cell carcinoma trials. Although still in early stages, we believe this clinical strategy will continue to build significant value in G-202 and in the company. We are particularly excited by the potential that G-202 is showing as a treatment for patients with liver cancer, a market which is expected to be at $1.5 billion by 2019."

Consider all my posts my opinion and not advice to buy or sell anything. I post on stocks I own or am considering owning. Do your own DD!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up